Preferred Name |
ibritumomab tiuxetan |
|
Synonyms |
IDEC-Y2B8 |
|
ID |
http://purl.bioontology.org/ontology/MESH/C422802 |
|
altLabel |
IDEC-Y2B8 IDEC-Y2B8 IDEC-129 yttrium-90-ibritumomab tiuxetan IDEC-129 Zevalin |
|
cui |
C5441861 C1134535 C0919274 C0879283 C0877880 |
|
HM |
D000911 |
|
II |
D015021 D018951 D016393 |
|
Inverse of RB |
4Q52C550XK 0 |
|
LT |
TRD |
|
Mapped to | ||
MDA |
20010329 |
|
MeSH Frequency |
452 |
|
MMR |
20191031 |
|
notation |
C422802 |
|
prefLabel |
ibritumomab tiuxetan |
|
SC |
1 |
|
Scope Statement |
90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma |
|
SRC |
Semin Oncol 2000 Dec;27(6 Suppl 12);74-8 |
|
TERMUI |
T441149 T000966179 T000966178 T696262 T441147 T441148 |
|
TH |
US NLM (2020) FDA SRS (2017) NLM (2001) USAN (19XX) INN (19XX) NLM (2007) |
|
tui |
T116 T129 T121 |
Create mapping